PROEHL GERALD T - 01 Jul 2025 Form 4 Insider Report for TENAX THERAPEUTICS, INC. (TENX)

Role: Director
Signature: /s/ S. Halle Vakani, as Attorney-in-Fact
Issuer symbol: TENX
Transactions as of: 01 Jul 2025
Net transactions value: $0
Form type: 4
Filing time: 03 Jul 2025, 08:11:17 UTC
Previous filing: 23 Jan 2025
Next filing: 29 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
PROEHL GERALD T	Director	101 GLEN LENNOX DRIVE, SUITE 300, CHAPEL HILL	/s/ S. Halle Vakani, as Attorney-in-Fact	03 Jul 2025	0001279191

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	TENX	Common Stock						1,667	01 Jul 2025	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TENX	Stock Option (right to buy)	Award	$0	+80,000	$0.000000	80,000	01 Jul 2025	Common Stock	80,000	$5.75	Direct
holding	TENX	Stock Option (right to buy)					1	01 Jul 2025	Common Stock	1	$9968.00	Direct
holding	TENX	Stock Option (right to buy)					1	01 Jul 2025	Common Stock	1	$1056.00	Direct
holding	TENX	Stock Option (right to buy)					4	01 Jul 2025	Common Stock	4	$3200.00	Direct
holding	TENX	Stock Option (right to buy)					4	01 Jul 2025	Common Stock	4	$992.00	Direct
holding	TENX	Stock Option (right to buy)					100,000	01 Jul 2025	Common Stock	100,000	$5.94	Direct
holding	TENX	Pre-Funded Warrant					31,654	01 Jul 2025	Common Stock	31,654	$0.0100	Direct	F1
holding	TENX	Warrant					16,660	01 Jul 2025	Common Stock	16,660	$4.50	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The pre-funded warrant has no expiration date.
F2	The warrant will expire on the earlier of (i) thirty (30) trading days following the date of the Issuer's initial public announcement of topline data from its Phase 3 LEVEL Study (LEVosimendan to Improve Exercise Limitation in PH-HFpEF Patients) (NCT05983250 ) (the "Topline Data Announcement"); (ii) proportionally upon the exercise of the Reporting Person's pre-funded warrant issued on August 8, 2024, if such exercise is prior to the Topline Data Announcement; and (iii) August 8, 2029.

Content

The pre-funded warrant has no expiration date.

The warrant will expire on the earlier of (i) thirty (30) trading days following the date of the Issuer's initial public announcement of topline data from its Phase 3 LEVEL Study (LEVosimendan to Improve Exercise Limitation in PH-HFpEF Patients) (NCT05983250 ) (the "Topline Data Announcement"); (ii) proportionally upon the exercise of the Reporting Person's pre-funded warrant issued on August 8, 2024, if such exercise is prior to the Topline Data Announcement; and (iii) August 8, 2029.